Science 

The growing potential of a Filamin A (FLNA) Modulator.

Overview  

Simufilam is a proprietary, orally administered small molecule designed to modulate the function of FLNA, a scaffolding protein implicated in neuronal morphology and signaling. This mechanism supports simufilam’s first-in-class potential in tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A.   

How it may work  

• In preclinical research, simufilam alleviated neuronal and circuit abnormalities leading to a reduction of seizure activity.
• Independent work conducted by the TSC Alliance Preclinical Consortium showed that simufilam attenuated the progression of seizure activity in a dose-dependent manner in Tsc1 conditional knockout mice.  

Key attributes  

• Oral, small-molecule approach intended to be compatible with chronic administration.  
• Human pharmacokinetics (legacy clinical data): elimination half-life ~4.5 hours with ~30% accumulation after 28 days of twice-daily dosing—parameters that help inform dose-finding in future studies.  
• Mechanism and clinical potential remain under investigation.